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MYB controls erythroid versus megakaryocyte lineage
fate decision through the miR-486-3p-mediated
downregulation of MAF
E Bianchi1, J Bulgarelli1, S Ruberti1, S Rontauroli1, G Sacchi1, R Norfo1, V Pennucci1, R Zini1, S Salati1, Z Prudente1, S Ferrari2
and R Manfredini*,1
The transcription factor MYB has a key role in hematopoietic progenitor cells (HPCs) lineage choice, by enhancing erythropoiesis
at the expense of megakaryopoiesis. We previously demonstrated that MYB controls erythroid versus megakaryocyte lineage
decision by transactivating KLF1 and LMO2 expression. To further unravel the molecular mechanisms through which MYB affects
lineage fate decision, we performed the integrative analysis of miRNA and mRNA changes in MYB-silenced human primary CD34+
HPCs. Among the miRNAs with the highest number of predicted targets, we focused our studies on hsa-miR-486-3p by
demonstrating that MYB controls miR-486-3p expression through the transactivation of its host gene, ankyrin-1 (ANK1) and that
miR-486-3p affects HPCs commitment. Indeed, overexpression and knockdown experiments demonstrated that miR-486-3p
supports the erythropoiesis while restraining the megakaryopoiesis. Of note, miR-486-3p also favors granulocyte differentiation
while repressing the macrophage differentiation. To shed some light on the molecular mechanisms through which miR-486-3p
affects HPCs lineage commitment, we profiled the gene expression changes upon miR-486-3p overexpression in CD34+ cells.
Among the genes downregulated in miR-486-3p-overexpressing HPCs and computationally predicted to be miR-486-3p targets, we
identified MAF as a miR-486-3p target by 30UTR luciferase reporter assay. Noteworthy, MAF overexpression was able to partially
reverse the effects of miR-486-3p overexpression on erythroid versus megakaryocyte lineage choice. Moreover, the MYB/MAF
co-silencing constrained the skewing of erythroid versus megakaryocyte lineage commitment in MYB-silenced CD34+ cells, by
restraining the expansion of megakaryocyte lineage while partially rescuing the impairment of erythropoiesis. Therefore, our data
collectively demonstrate that MYB favors erythropoiesis and restrains megakaryopoiesis through the transactivation of miR-486-
3p expression and the subsequent downregulation of MAF. As a whole, our study uncovers the MYB/miR-486-3p/MAF axis as a new
mechanism underlying the MYB-driven control of erythroid versus megakaryocyte lineage fate decision.
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The transcription factor MYB (v-myb avianmyeloblastosis viral
oncogene homolog, c-myb) has a pivotal role in the
hematopoietic system development and adult hematopoietic
progenitor cells (HPCs) lineage commitment, as demon-
strated by in vivo knockout/knockdown models1,2 and in vitro
silencing approaches.3
Despite the broad bibliography dealing with the function of
MYB in hematopoiesis, the molecular mechanisms under-
lying the role of this transcription factor in hematopoietic
differentiation are still partially unknown. More in detail,
several in vivo models demonstrate that the knockout/knock-
down of MYB impairs erythropoiesis1,2 and the reduction of its
transcriptional activity causes an abnormal expansion of
magakaryocytopoiesis.4–6 Nevertheless, the transcriptional
targets of MYB that could explain these effects still remain
uncovered. For this purpose, we previously demonstrated that
MYB affects erythroid versus megakaryocyte commitment by
transactivating the expression of the transcription factors
KLF17,8 and LMO2.3,9 At the same time, gene expression
profiling (GEP) data from MYB-silenced hematopoietic pro-
genitor cells (HPCs) highlighted the upregulation of several
transcription factors having a pivotal role in hematopoiesis and
potentially involved in MYB-directed HPCs lineage choice,
such as MAF,10,11 MAFB12 and MEIS1.13 However, ChIP data
showed that these genes are not direct transcriptional targets
of MYB,3 that is, MYB is unable to directly bind their promoter
regions by repressing their expression. Therefore, the
mechanisms through which they are modulated upon MYB
silencing remains to be clarified.
For this purpose, we decided to unravel the microRNA
(miRNA) and the mRNA expression changes induced by
MYB silencing in cord blood (CB)-derived CD34+ HPCs.
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Indeed, increasing evidences stress the key role of miRNAs in
controlling many cellular processes including hematopoietic
lineage commitment14,15 through the post-transcriptional
repression of their target genes,16 mainly by mRNA degrada-
tion or inhibition of protein translation.
In order to unveil whether the MYB-regulatedmiRNAs could
further exlplain the role of MYB in promoting erythropoiesis
and repressing megakaryopoiesis, GEP and miRNA expres-
sion profiling (miEP) data from MYB-silenced HPCs
were integrated in silico by using QIAGEN's Ingenuity
Pathway Analysis Software (IPA, QIAGEN, Redwood City, CA,
USA; www.qiagen.com/ingenuity). IPA analysis disclosed
242 miRNA–mRNA pairs differentially expressed in MYB-
silenced compared with control CD34+ cells and with anti-
correlated expression trend. Among the miRNAs with the
highest number of putative targets, that is, mRNAs having an
anti-correlated expression pattern, we focused our attention
on hsa-miR-486-3p (hereafter reported as miR-486-3p) as
downregulated upon MYB silencing together with the host
gene ankyrin-1 (ANK1). Our data demonstrate that MYB
affects HPCs fate decision through the transcriptional control
of miR-486-3p expression.
Results
mRNA and miRNA expression profiling in CD34+ HPCs
upon MYB silencing. To shed some light on the MYB-driven
miRNA-mediated regulation of gene expression during HPCs
lineage commitment, we profiled the mRNA and miRNA
expression changes induced by MYB silencing in human
CD34+ cells. RNAi-mediated experiments were performed by
nucleofection of MYB-targeting siRNAs (Supplementary
Table S1), as previously detailed.3,17 For each experiment,
one sample transfected with a non-targeting siRNA as a
negative control (NegCTRsiRNA) was performed besides
the MYB-targeting siRNA-transfected sample (MYBsiRNA).
As previously shown,3 in these experimental conditions the
best downregulation of MYB protein levels is achieved at 24 h
after the last of three 24 hours spaced nucleofection cycles
(hereafter reported as post nucleofection) in CD34+ cells;
therefore, we selected this time point for studying the mRNA
and miRNA expression changes induced by MYB silencing
during HPCs commitment. In a set of five independent
experiments, MYBsiRNA and NegCTR CD34+ cells were
profiled for mRNA and miRNA expression by Affymetrix U219
Array (Affymetrix; Santa Clara, CA, USA) and Exiqon Human
miRNome PCR Panel (Exiqon, Copenhagen, Denmark),
respectively. GEP and miEP analysis disclosed 616 DEGs
and 37 differentially expressed miRNAs (DEMs) between
MYBsiRNA and NegCTRsiRNA samples (Supplementary
Tables S2 and S3; DEGs upon MYB silencing were also
profiled at 24 hours after one and two nucleofection cycles:
GEP data were deposited in the GEO repository; see the
Materials and Methods section).
Next, in order to build the regulatory networks between the
miRNAs and their predicted targets modulated by MYB
silencing, in silico integrative analysis by means of IPA was
performed. IPA analysis highlighted 20 DEMswith at least one
anti-correlated target among DEGs, and 150 DEGs with at
least one anti-correlated targeting DEM, overall describing
242miRNA–mRNA pairs with anti-correlated expression trend
(Supplementary Table S4).
Among the 20 DEMs from IPA analysis, we focused our
attention on hsa-miR-486-3p as one of the miRNAs
downregulated upon MYB silencing and displaying the
highest number of putative targets (Table 1, Supplementary
Figure S1). Notably, miR-486-3p is an intragenic (intronic)
miRNA (Figure 1a) whose host gene, ankyrin-1 (ANK1) was
similarly downregulated upon MYB silencing (Supplementary
Table S2).
MYB-dependent transcriptional control of ANK1 and
miR-486-3p. To get further insights into the relationship
Table 1 DEMs from integrated miRNA-mRNA analysis on MYB-silenced CD34+ HPCs
miRNA ID miRNA family Fold Change in MYB-silenced
versus control CD34+ cells
Number of anti-correlated
putative targets
hsa-miR-144-3p miR-144-3p (miRNAs w/seed ACAGUAU) − 3.245 31
hsa-miR-486-3p miR-486-3p (and other miRNAs w/seed GGGGCAG) − 3.201 26
hsa-miR-152 miR-148b-3p (and other miRNAs w/seed CAGUGCA) − 1.972 24
hsa-miR-92b-3p miR-92a-3p (and other miRNAs w/seed AUUGCAC) − 2.542 19
hsa-miR-491-5p miR-491-5p (and other miRNAs w/seed GUGGGGA) − 1.647 16
hsa-miR-671-5p miR-671-5p (miRNAs w/seed GGAAGCC) − 2.844 16
hsa-miR-197-3p miR-197-3p (and other miRNAs w/seed UCACCAC) − 1.625 14
hsa-miR-339-5p miR-339-5p (and other miRNAs w/seed CCCUGUC) − 1.524 14
hsa-miR-545-3p miR-545-3p (miRNAs w/seed CAGCAAA) − 2.336 11
hsa-miR-520h miR-520g-3p (and other miRNAs w/seed CAAAGUG) − 2.564 10
hsa-miR-877-5p miR-877-5p (and other miRNAs w/seed UAGAGGA) − 2.003 10
hsa-miR-296-3p miR-296-3p (miRNAs w/seed AGGGUUG) − 4.443 9
hsa-miR-362-5p miR-362-5p (and other miRNAs w/seed AUCCUUG) − 1.701 9
hsa-miR-151a-3p miR-151-3p (and other miRNAs w/seed UAGACUG) − 1.989 8
hsa-miR-335-5p miR-335-5p (and other miRNAs w/seed CAAGAGC) 1.516 8
hsa miR-486-5p miR-486-5p (and other miRNAs w/seed CCUGUAC) − 3.002 6
hsa-miR-151a-5p miR-151-5p (and other miRNAs w/seed CGAGGAG) − 1.571 5
hsa-miR-376b-3p miR-376a-3p (and other miRNAs w/seed UCAUAGA) 1.625 5
hsa-miR-191-5p miR-191-5p (and other miRNAs w/seed AACGGAA) − 1.696 2
hsa-miR-337-5p miR-337-5p (miRNAs w/seed AACGGCU) − 1.643 2
Abbreviations: DEMs, differentially expressed miRNAs; HPCs, hematopoietic progenitor cells; miRNA, microRNA
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between the silencing of MYB and the downregulation of
miR-486-3p/ANK1, we detected the kinetics of miR-486-3p
and ANK1 mRNA expression during HPCs erythroid differ-
entiation. We found that both miR-486-3p and the ANK1
were strongly upregulated during erythroid differentiation
(Figure 1b), further supporting the notion that miR-486-3p
expression is regulated by the promoter region of the host
ANK1 gene.18–20
Next, we screened the ANK1 promoter region for putative
MYB binding sites by matching the genomic sequence
upstream the ANK1 gene transcription starting site (TSS) to
the TRANSFAC consensus-binding sequences21 (http://www.
cbrc.jp/research/db/TFSEARCH.html). Computational screening
highlighted the presence of two putative binding sites for
MYB with high scores (based on the TRANSFAC positional
weight matrix for MYB) localized within 2000 bps upstream the
ANK1 gene TSS (Supplementary Table S5). Therefore, we
checked the ANK1 promoter region for the direct binding of
MYB by Chromatin Immunoprecipitation (ChIP).3
ChIP experiments in CD34+ cells demonstrated the direct
binding of MYB to the ANK1 promoter in vivo. In fact, MYB
antibody-mediated immunoprecipitation resulted in amplifica-
tion of the ANK1 promoter region, while immunoprecipitation
without antibody or with an isotype-matched control antibody
determined a negligible amplification (Figure 1c).
In addition, luciferase reporter assays demonstrated that
MYB is able to transactivate ANK1 promoter, as increasing
doses of MYB-coding vector caused a dose-dependent
increase in ANK1 promoter-driven luciferase expression
(Figure 1d).
Overall, these data indicated that MYB is able to bind to
ANK1 promoter and to transactivate the expression of both the
ANK1 gene and the embedded miR-486-3p.
miR-486-3p affects erythroid versus megakaryocyte
lineage fate decision in HPCs. In order to understand
whether miR-486-3p could be relevant for MYB-driven HPCs
fate decision, we studied the effects of its overexpression by
means of miR-486-3p mimic transfection (miR-486-3p
mimic), compared with a negative control mimic-transfected
sample (NegCTR mimic), in CB CD34+ cells. Similarly, we
assayed the effects of miR-486-3p knockdown by the
nucleofection of miR-486-3p and non-targeting control
inhibitors (miR-486-3pInh/NegCTRInh) in CD34+ cells.
Furthermore, in order to clarify whether the MYB-dependent
miR-486-3p expression could be relevant in MYB-mediated
control of erythroid versus megakaryocyte lineage fate
decision, we studied the effects of the rescue of miR-486-3p
expression in MYB-silenced HPCs through the co-transfection
of MYB-targeting siRNAs and miR-486-3p mimics in
CD34+ cells.
The effects of miR-486-3p overexpression and knockdown
on CD34+ cells commitment were evaluated by flow-
cytometric analysis of differentiation markers and morpholo-
gical analysis of May–Grunwald–Giemsa- (MGG) stained
cytospins in unilineagemegakaryocyte, erythroid, granulocyte
and mono-macrophage cultures (Figures 2–4).
Our data demonstrated that miR-486-3p overexpression
restrains megakaryocyte differentiation. Indeed, flow cyto-
metry data highlighted a reduction of the megakaryocyte-
Figure 1 MYB-driven regulation of the ANK1 gene and the embedded miR-486-
3p expression. (a) miR-486 is under the transcriptional regulation of the ankyrin 1
(ANK1) locus; data from UCSC Human Genome Browser-hg19 assembly.
(b) miR-486-3p and ANK1 expression kinetics during erythroid differentiation of CD34
+ cells. The expression levels of miR-486-3p and ANK1 mRNA were monitored by qRT-
PCR at different culture time points after the EPO-driven induction of the erythroid
differentiation in CD34+ cells. miR-486-3p mature miRNA and ANK1 mRNA levels were
normalized versus housekeeping U6 snRNA and HPRT1 mRNA, respectively, and are
reported asRQ respect to CD34+ cells at time 0 of treatment with EPO, which was set as
calibrator. P≤ 0.05 at day 4 and day 6 compared with t0 for both miR-486-3p and ANK1.
(c) ANK1 promoter-specific PCR performed in a representative ChIP experiment. PCR
data are reported for both the putative MYB binding sites with the highest computational
prediction scores (i.e.− 1292/− 1287 and− 1008/− 999, see Supplementary Table S5
for further details). ChIP and PCRs were performed in triplicate. (d) MYB transactivation
of ANK1 promoter-driven luciferase expression. The amounts (in ng) of co-transfected
plasmids are reported. Renilla-normalized Firefly luciferase levels (mean± S.E.M.;
n= 5) are normalized by setting the pXP1-ANK1(−1498/+47)/pCMV6XL5
empty vector-transfected sample as= 1. Error bars represent S.E.M. **P≤ 0.01
compared with pXP1ANK1(−1498/+47)/pCMV6XL5 empty vector-transfected
sample. n= number of experiments
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committed population from the earlier CD34+CD41+ to the
more mature CD34-CD41+, CD41+CD42b− and CD41+
CD42b+ fractions in miR486-3p mimic compared with
NegCTR mimic cells at 4 days of culture (Figure 2a,
Supplementary Figure S2Ai). The mature megakaryocytic
CD41+CD42b+ population was similarly reduced upon
miR-486-3p overexpression at later stages (Figure 2b,
Supplementary Figures S2Aii-iii and S2B). Consistently,
morphological analysis highlighted the impairment of mega-
karyocyte differentiation in miR-486-3p mimic (Figure 2ci)
compared with NegCTR mimic sample (Figure 2cii). The
perturbation of megakaryopoiesis was further demonstrated
by the striking reduction in megakaryocyte hyperploid and
proplatelet-producing cells detected in miR-486-3p mimic
compared with NegCTR mimic cells in culture (Figure 2d).
We also studied the effects of miR-486-3p overexpression
on megakaryocyte commitment by plating miR-486-3p and
NegCTR mimic CD34+ cells in a collagen-based serum-free
semisolid medium supporting the megakaryopoiesis in vitro.
This assay demonstrated that miR-486-3p overexpression
strongly represses the megakaryocyte commitment. Notably,
the megakaryocyte colony forming units (CFU-MKs) scoring
showed remarkable differences in medium and small CFU-
MKs between miR-486-3p mimic and NegCTR samples
(Figure 2e, Supplementary Figure S2C), further demonstrat-
ing that miR-486-3p overexpression affects both early and late
steps of megakaryocyte differentiation.
The effects of miR-486-3p knockdown were similarly
assessed, by highlighting an increase in megakaryocyte
differentiation at both early (CD34+CD41+ fraction,
Figure 2f) and late differentiation steps (CD41+CD42b- and
CD41+CD42b+ fractions at 8 and 12 days, Figures 2g and h).
The same trend was confirmed by the increase in CFU-MKs
inmiR-486-3pInh comparedwithNegCTRInh sample (Figure 2i).
Finally, MYB-targeting siRNAs/miR-486-3p mimics
co-transfection experiments showed a reduction of both early
CD34+CD41+ (Figure 2j) and more differentiated CD41+
CD42b+ population (Figures 2j and k) in MYBsiRNA/miR-486-
3p mimic compared with MYBsiRNA/NegCTR mimic sample.
Similarly, a remarkable CFU-MKs reduction was detected in
MYBsiRNA/miR-486-3p mimic compared with MYBsiRNA/
NegCTR mimic sample (Figure 2l).
Next, we studied the effects of miR-486-3p overexpression
in CD34+ cells erythroid differentiation, by demonstrating that
miR-486-3p enhances the erythropoiesis. Indeed,miR-486-3p
overexpression caused an early increase in the erythroid
CD36+GPA+ fraction (Figure 3a), followed by an expansion
of the more mature CD36-GPA+ population at the later
stages of erythroid differentiation (Figure 3a, Supplementary
Figure S2D). In line with these data, morphological analysis
higlighted an enrichment of orthochromatic erythroblasts with
pyknotic nuclei and reticulocytes representing the last stages
of erythropoiesis in miR-486-3p mimic samples (Figure 3bii),
while NegCTR mimic samples were mainly represented by
more immature cells, such as proerythroblasts and basophilic
erythroblasts (Figure 3bi). Conversely, miR-486-3p knock-
down in HPCs was able to negatively interfere with the
erythroid differentiation, as demonstrated by the reduction in
the CD36+GPA− and CD36+GPA+ fractions at 4 days post
nucleofection (Figure 3c), and the subsequent decrease in
CD36+GPA+ and CD36-GPA+ populations at 8 and 12 days,
respectively (Figures 3d and e).
Noteworthy, the arrest in the early CD71+CD36-/CD71+
CD36+ transition and in the late CD36+GPA+/CD36-GPA+
maturation steps of erythropoiesis (Figures 3f and g;MYBsiRNA/
NegCTR mimic sample) induced by MYB silencing was partially
reversed by the miR-486-3p mimic co-transfection (Figures 3f
and g; MYBsiRNA/miR-486-3p mimic sample).
Collectively these results demonstrate that the MYB-driven
miR-486-3p expression during HPCs commitment favors
erythroid differentiation while restraining the megakaryocyte
differentiation.
Figure 2 Effects of miR-486-3p overexpression, miR-486-3p knockdown and miR-486-3p rescue upon MYB silencing on megakaryocyte differentiation. (a) Flow cyto-
metric analysis (mean±S.E.M.; n= 4) of CD34, CD41 and CD42b expression at day 4 of megakaryocyte unilineage culture post nucleofection. (b) Flow cytometric analysis
(mean±S.E.M.; n= 4) of CD41 and CD42b expression at day 12 of megakaryocyte unilineage culture post nucleofection. (c) Morphological analysis of NegCTR mimic (i) and
miR-486-3p mimic-transfected cells (ii) after May–Grünwald–Giemsa staining at day 8 of megakaryocyte unilineage culture post nucleofection in a representative experiment.
Magnification, × 1000. (d) Culture micrographs of NegCTR mimic (i) and miR-486-3p mimic-transfected cells (ii) at day 11 of megakaryocyte culture at × 200 magnification in a
representative experiment. NegCTR mimic sample (i) shows the large, polyploid cells together with several proplatelet-forming (see black arrows) cells, which are almost
undetectable in miR-486-3p-overexpressing sample (ii). (e) Megakaryocyte clonogenic assay results (mean± S.E.M.; n= 4). CFU-MKs were scored according to the
manufacturer’s protocol based on their size, which reflects the maturation stage of the progenitor giving rise to each colony, as large (450 cells, arising from more primitive MK
progenitors), medium (21–49 cells) and small (3–21 cells, deriving from more mature megakaryocyte progenitors) colonies. The cells were plated 24 hours after the last
nucleofection and scored after 12 days. Values are reported as number of megakaryocyte colonies for 4000 plated cells. *P≤ 0.05, **P≤ 0.01 and ***P≤ 0.001 in miR-486-3p
mimic compared with NegCTR mimic sample. The efficient upregulation of miR-486-3p expression upon mimic transfection was checked at 24 hours post nucleofection by qRT-
PCR (RQ± SE, 74.4± 19.2, Po0.05) (f–h) Flow cytometric analysis (mean±S.E.M.; n= 3) of CD34, CD41 and CD42b expression at day 4 (f) and CD41 and CD42b at day 8
(g) and day 12 (h) of megakaryocyte unilineage culture post nucleofection with miR-486-3p/NegCTR inhibitor. (i) Megakaryocyte clonogenic assay results (mean± S.E.M.; n= 3)
for miR-486-3p and NegCTR Inhibitor-transfected CD34+ cells. CFU-MKs were scored according to the manufacturer’s protocol based on their size, as reported above. Values
are reported as number of megakaryocyte colonies for 4000 plated cells. *P≤ 0.05 in miR-486-3p inhibitor compared with NegCTR-inhibitor sample. The efficient knockdown of
miR-486-3p expression upon inhibitor transfection was checked at 24 hours post nucleofection by qRT-PCR (RQ±SE, 0.593± 0.161, Po0.05) (j and k) Flow cytometric
analysis (mean±S.E.M.; n= 3) of CD34, CD41 and CD42b expression at day 4 (j) and CD41 and CD42b at day 12 (k) of megakaryocyte unilineage culture post nucleofection
with MYBsiRNA/NegCTRsiRNA and/or miR-486-3p/NegCTR mimics. (l) Megakaryocyte clonogenic assay results (mean± S.E.M.; n= 3) for CD34+ cells transfected with
MYBsiRNA/NegCTRsiRNA and/or miR-486-3p/NegCTR mimic. CFU-MKs were scored according to the manufacturer’s protocol based on their size, as reported above. Values
are reported as number of megakaryocyte colonies for 4000 plated cells. *P≤ 0.05, **P≤ 0.01 and ***P≤ 0.001. MYB and miR-486-3p expression levels were checked at
24 hours post nucleofection by qRT-PCR (RQ±SE, 0.423± 0.122 in MYBsiRNA/NegCTR mimic and 0.487± 0.148 in MYBsiRNA/miR-486-3p mimic forMYB; 75.821± 13.347
in NegCTRsiRNA/miR-486-3p mimic and 70.382± 11.027 in MYBsiRNA/miR-486-3p mimic for miR-486-3p levels; NegCTRsiRNA/NegCTR mimic set as calibrator).
Abbreviations: CFU, colony forming unit; MK, megakaryocyte; MYBsiRNA, MYB-targeting siRNA; NegCTR inhibitor, negative control inhibitor; NegCTR mimic, negative control
mimic; NegCTRsiRNA, negative control siRNA; and n= number of experiments
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Figure 3 Effects of miR-486-3p overexpression, miR-486-3p knockdown and miR-486-3p rescue upon MYB silencing on erythroid differentiation. (a) Flow cytometric
detection (mean±S.E.M.; n= 4) of CD36 and GPA (intermediate and late erythroid markers, respectively) at days 4, 8 and 12 of erythroid unilineage culture post nucleofection.
*P≤ 0.05 and **P≤ 0.01 in miR-486-3p mimic compared with NegCTR mimic sample. (b) Morphological analysis of NegCTR (i) and miR-486-3p mimic-transfected cells (ii) after
May–Grünwald–Giemsa staining at day 8 of erythroid unilineage culture post nucleofection in a representative experiment. Magnification, × 400. NegCTR mimic sample (i)
displays more immature cells such as proerythroblasts and basophilic erythroblasts (see black arrows), while miR-486-3p mimic sample (ii) is enriched in cells from later steps of
erythroid differentiation such as orthocromatic erythroblasts (see black arrows) together with nuclear extrusion phenomena (see asterisks) and enucleated reticulocytes/
erythrocytes. The efficient upregulation of miR-486-3p expression upon mimic transfection was checked at 24 hours post nucleofection by qRT-PCR (RQ± SE, 74.4± 19.2,
Po.05) (c–e) Flow cytometric detection (mean±S.E.M.; n= 3) of CD36 and GPA at days 4 (c), 8 (d) and 12 (e) of erythroid unilineage culture post nucleofection with miR-486-
3p/NegCTR inhibitors. *P≤ 0.05 in miR-486-3p inhibitor compared with NegCTR inhibitor sample. The efficient knockdown of miR-486-3p expression upon inhibitor transfection
was checked at 24 hours post nucleofection by qRT-PCR (RQ±SE, 0.593± 0.161, Po.05) (f, g) Flow cytometric data (mean± S.E.M.; n= 3) for the expression of CD71, CD36
and GPA (early, intermediate and late erythroid markers, respectively) during erythroid unilineage culture. Data reported in the graphs display the percentages of CD71+CD36-
(early erythroid) and CD71+CD36+ (intermediate erythroid cells) at day 4 (f) and the fractions of CD36+GPA- (intermediate), CD36+GPA+ (more mature) and CD36-GPA+ (late)
erythroid cells (g) at day 8 of erythroid unilineage culture post nucleofection with MYBsiRNA/NegCTRsiRNA and/or miR-486-3p mimic/NegCTR mimic. *P≤ 0.05, **P≤ 0.01 and
***P≤ 0.001. MYB and miR-486-3p expression levels were checked at 24 hours post nucleofection by qRT-PCR (RQ± SE, 0.423± 0.122 in MYBsiRNA/NegCTR mimic and
0.487± 0.148 in MYBsiRNA/miR-486-3p mimic for MYB; 75.821± 13.347 in NegCTRsiRNA/miR-486-3p mimic and 70.382± 11.027 in MYBsiRNA/miR-486-3p mimic for
miR-486-3p levels; NegCTRsiRNA/NegCTR mimic set as calibrator). Abbreviations: GPA, glycophorin A; MYBsiRNA, MYB-targeting siRNA; NegCTR mimic, negative control
mimic; NegCTR inhibitor, negative control inhibitor; NegCTRsiRNA, negative control siRNA; n= number of experiments
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Figure 4 Effects of miR-486-3p overexpression and miR-486-3p knockdown on CD34+ cells granulocyte and mono-macrophage differentiation. (a) Flow cytometric detection
(mean±S.E.M.; n= 4) of granulocyte MPO and CD15 and megakaryocyte CD41 markers at day 10 of granulocyte unilineage culture post nucleofection. (b) Flow cytometric
detection (mean±S.E.M.; n= 4) of mono-macrophage CD14, macrophage-specific CD163 and megakaryocyte CD41 differentiation markers at day 10 of mono-macrophage
unilineage culture post nucleofection. *P≤ 0.05 and **P≤ 0.01 in miR-486-3p mimic compared with NegCTR mimic sample. (c) Morphological analysis of NegCTR (i, iii, v) and
miR-486-3p mimic-transfected cells (ii, iv, vi) after May–Grünwald–Giemsa staining at days 11 (i, ii) and 13 (iii, iv) of granulocyte and day 13 (v, vi) of mono-macrophage unilineage
culture post nucleofection in a representative experiment. GCSF-driven granulocyte unilineage culture highlighted at day 11 post nucleofection in NegCTR mimic sample (i) a
higher fraction of more immature cells such as promyelocytes (see white asterisk) and neutrophilic metamyelocytes (black arrows), while miR-486-3p mimic sample (ii) was
enriched in more mature cells, such as two-lobed (black asterisk) and segmented neutrophils (black arrows). Similarly, at 13 days of granulocyte unilineage culture NegCTRmimic
sample (iii) presented a more immature phenotype, mainly represented by neutrophilic metamyelocytes (white asterisks) and neutrophilic band cells (black arrows), while
miR-486-3p mimic sample (iv) was enriched in two-lobed (black asterisks) and segmented neutrophils (black arrows), representing the last steps of granulocyte differentiation. By
contrast, morphological analysis at day 13 of MCSF-driven mono-macrophage unilineage culture showed a uniform macrophage morphology in NegCTR cells (v), while miR-486-
3p-overexpressing cells (vi) still displayed a large portion of monocytes besides terminally differentiated macrophages. Magnification, × 1000. The efficient upregulation of
miR-486-3p expression upon mimic transfection was checked at 24 hours post nucleofection by qRT-PCR (RQ± SE, 74.4± 19.2, Po.05) (d and e) Flow cytometric detection
(mean±S.E.M.; n= 3) of granulocyte MPO and CD15 at day 10 of granulocyte unilineage culture (d) and of mono-macrophage CD14 and macrophage-specific CD163
differentiation markers at day 6 of mono-macrophage unilineage culture post nucleofection (e) with miR-486-3p/NegCTR inhibitors. *P≤ 0.05 and **P≤ 0.01 in miR-486-3p
inhibitor compared with NegCTR inhibitor sample. The efficient knockdown of miR-486-3p expression upon inhibitor transfection was checked at 24 hours post nucleofection by
qRT-PCR (RQ±SE, 0.593± 0.161, Po0.05). Abbreviations: GCSF, granulocyte colony stimulating factor; MCSF, macrophage colony stimulating factor; MPO,
Myeloperoxidase; NegCTR mimic, negative control mimic; NegCTR inhibitor, negative control inhibitor; n= number of experiments
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miR-486-3p favors granulocyte differentiation while
repressing macrophage differentiation in HPCs. We
further investigated the effects of miR-486-3p overexpression
and knockdown in HPCs granulocyte and mono-macrophage
differentiation by morphological and immunophenotypic
analyses (Figure 4).
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These experiments allowed us to demonstrate that
miR-486-3p expression promotes granulocyte differentiation,
while suppressing macrophage differentiation. Indeed, an
increase in granulocyte lineage-specific MPO+ and CD15+
populations (Figure 4a, Supplementary Figure S2E) was
detected in miR-486-3p mimic compared with NegCTR mimic
sample during the granulocyte differentiation. In addition,
morphological analysis clearly displayed an enrichment of
cells at the later stages of granulocyte differentiation in
miR-486-3p-overexpressing samples (Figure 4cii, iv) com-
pared with the controls, still showing a higher fraction of more
immature cells (Figure 4ci, iii).
Moreover, miR-486-3p overexpression negatively interfered
with MCSF-driven mono-macrophage differentiation, as
demonstrated by the reduction of the CD14+CD163+
macrophage population respect to the more immature
CD14+CD163- fraction in miR-486-3p-overexpressing cells
(Figure 4b and Supplementary Figure S2F). Indeed, macro-
phage differentiation-inducing conditions determined a homo-
geneous macrophage morphology in NegCTR mimic cells
(Figure 4cv), while miR-486-3p mimic sample still showed a
mixed monocyte/macrophage population (Figure 4cvi).
Conversely, miR-486-3p knockdown impaired the granulo-
cyte differentiation, as demonstrated by the reduction in
MPO+ and CD15+ fractions (Figure 4d) while causing an
early increase in the CD14+CD163+ macrophage population
(day 6, Figure 4e).
Overall, miR-486-3p overexpression and knockdown data
show that miR-486-3p affects HPCs granulocyte versus
mono-macrophage lineage choice, by promoting the granulo-
cyte differentiation while constraining the macrophage
differentiation. Consistently, the detection of miR-486-3p
expression by quantitative real-time PCR (qRT-PCR)
during granulocyte and mono-macrophage differentiation
showed an early upregulation of miR-486-3p upon G-CSF-
driven induction of granulocyte differentiation (Supplementary
Figure S3A), while the miRNA is progressively downregulated
during the mono-macrophage differentiation (Supplementary
Figure S3B).
Gene expression profile of miR-486-3p-overexpressing
HPCs and functional validation of MAF as a miR-486-3p
target. In order to unravel the molecular mechanisms
underlying the effects of miR-486-3p in HPCs lineage
commitment and to understand how the MYB-driven trans-
activation of miR-486-3p expression can contribute to explain
the role of MYB in HPCs fate decision, we investigated the
transcriptional changes induced by miR-486-3p overexpres-
sion in HPCs.
In a set of three independent experiments, miR-486-3p
mimic and NegCTR mimic-transfected CD34+ cells were
profiled by Affymetrix U219 Array (Supplementary Table S6).
Next, in order to identify the transcripts sharing a differential
expression upon MYB silencing and miR-486-3p overexpres-
sion, we crossed the lists of transcripts modulated after
miR-486-3p overexpression (Supplementary Table S6) and
MYB silencing (Supplementary Table S2). The resulting list
was represented by 18 genes with anti-correlated expression
trend betweenmiR-486-3p-overexpressing andMYB-silenced
cells (Figure 5a). Among them, only the MAF (v-maf
musculoaponeurotic fibrosarcoma oncogene homolog, avian,
c-maf) transcript was downregulated upon miR-486-3p over-
expression and displayed the putative miR-486-3p target sites
in the 30-UTR based on TargetScan database (http://www.
targetscan.org), therefore being a predicted target for
miR-486-3p. For this reason, after qRT-PCR (RQ±SE,
0.235±0.065, Po0.01, n=4) and western blot (Figure 5b)
validation of MAF downregulation upon miR-486-3p over-
expression, we tested the miR-486-3p/MAF interaction by
luciferase reporter assay.
MAF gene encodes for two splicing variants, only the
transcript variant 2 showing a putative miR-486-3p target site
in the 30UTR (position 1380–1387 bps in 30UTR, sequence
50-CUGCCCCA-30). Figure 5c recapitulates reporter assays
results. The overexpression of miR-486-3p did not affect the
luciferase activity for the samples transfected with (1) no
30UTR (empty vector), (2) MAF variant 1 30UTR and (3) MAF
variant 2 30UTR, fragment 2530–4932 bps, both lacking
putative miR-486-3p-target sites. On the contrary, miR-486-
3p overexpression determined a reduction of luciferase
activity in the sample transfected with MAF variant 2 30UTR,
fragment 1–2569 bps, by demonstrating that miR-486-3p
targets MAF 30UTR.
Functional validation of the MYB/miR-486-3p/MAF axis in
megakaryocyte versus erythroid fate decision. At last, we
unraveled the role of MAF in MYB/miR-486-3p-mediated
skewing of erythroid versus megakaryocyte lineage choice.
For this purpose, we firstly checked by qRT-PCR the
expression of miR-486-3p and MAF during the megakaryo-
cyte and erythroid differentiation of CD34+ cells; we detected
an early downregulation of miR-486-3p (Figure 6ai) and the
simultaneous upregulation of MAF upon induction of the
megakaryocyte differentiation (Figure 6aii). On the contrary,
during the erythroid differentiation a progressive increase of
Figure 5 Gene expression profiling in miR-486-3p-overexpressing CD34+ cells and validation of the miR-486-3p/MAF 3´UTR interaction. (a) DEGs in miR-486-3p-
overexpressing compared with the NegCTR mimic-transfected CD34+ cells at 24 hours post nucleofection. DEGs in table are selected as modulated in both miR-486-3p-
overexpressing compared with NegCTR mimic cells and in MYB-silenced compared with NegCTRsiRNA cells. For both these comparisons, transcripts modulations are reported
as fold change. Transcripts in the table are ranked based on the fold change in miR-486-3p mimic compared with NegCTRmimic samples. Data for the computational prediction of
miR-486-3p targets from TargetScan are reported in the last column. (b) Western blotting analysis of MAF protein levels in protein lysates from miR-486-3p mimic-transfected
compared with NegCTR mimic-transfected CD34+ cells at 24 hours after the last of two nucleofection cycles (i.e. at the same time point selected for gene expression profiling).
β-actin protein levels are reported as loading control. (c) Renilla-normalized Firefly luciferase activity in K562 cells nucleofected with either a NegCTR mimic or a miR-486-3p
mimic and the indicated 3′untranslated region (30UTR) luciferase reporter vectors. Renilla-normalized Firefly luciferase activity (mean± S.E.M.; n= 3) was measured at 24, 48
and 72 hours post nucleofection. Each bar represents the luciferase activity upon miR-486-3p overexpression normalized to the value of the same 3′UTR luciferase vector upon
NegCTR mimic transfection. *Po0.05 compared with NegCTR mimic sample.
Role of MYB/miR-486-3p/MAF axis in hematopoiesis
E Bianchi et al
9
Cell Death and Differentiation
Role of MYB/miR-486-3p/MAF axis in hematopoiesis
E Bianchi et al
10
Cell Death and Differentiation
miR-486-3p (Figure 6bi) and a concurrent downregulation of
MAF (Figure 6bii) were detected.
These data unveiled an anti-correlated expression trend for
miR-486-3p andMAF during both the megakaryocyte and the
erythroid differentiation of HPCs, further supporting the idea of
a physiological role for miR-486-3p/MAF axis in erythroid
versus megakaryocyte fate decision.
Next, we investigated whether the rescue of MAF expres-
sion could restrain the effects of miR-486-3p overexpression
during the erythroid versus megakaryocyte lineage decision
by concurrently overexpressing miR-486-3p and MAF
in HPCs.
CD34+ cells were nucleofected with miR-486-3p or
NegCTR mimics and subsequently transduced with the
retroviral vector expressing the MAF coding sequence
(transcript variant 2, LMAFvar2IDN) or empty vector (LXIΔN).
As shown in Figure 6c, both the earlier CD41+CD42b-
population and the more mature CD41+CD42b+ fraction were
increased in LMAFvar2IDN/miR-486-3p compared with
LXIDN/miR-486-3p cells at 4 days of megakaryocyte uniline-
age culture. Similarly, the CFU-MK assay results displayed an
increase in CFU-MKs in LMAFvar2IDN/miR-486-3p sample
compared with LXIDN/miR-486-3p cells (Figure 6d). On the
contrary, the erythroid CD36+GPA- and CD36+GPA+ fractions
were reduced in LMAFvar2IDN/miR-486-3p cells compared
with LXIDN/miR-486-3p cells (Figure 6e). Collectively these
data demonstrate that the constitutive expression of MAF can
constrain the effects of miR-486-3p overexpression during the
erythroid versus megakaryocyte lineage choice.
Finally, in order to check whether the upregulation of MAF
could be relevant in the skewing of erythroid versus mega-
karyocyte fate decision upon MYB silencing, we studied the
effects of the siRNA-mediated silencing of MYB (MYBsiRNA;
Supplementary Table S1), MAF (MAFsiRNA; Supplementary
Table S1) or both (MYBsiRNA+MAFsiRNA) in CD34+ cells.
As shown in Figure 6f, the expansion of the megakaryocyte
lineage upon MYB silencing (MYBsiRNA) was restrained by
the co-silencing ofMAF (MYBsiRNA+MAFsiRNA), as demon-
strated by the reduction in CD41+ population (Figure 6f, see
also the CD41+CD42b- and CD41+CD42b+ populations at
8 and 12 days post nucleofection, respectively, Supplementary
Figures S4A and B).
In line with these data, the CFU-MK assay results
(Figure 6g, Supplementary Figure S4C) demonstrated that
the abnormal expansion of megakaryopoiesis in MYBsiRNA
sample was significantly constrained by the co-silencing of
MAF (MYBsiRNA+MAFsiRNA).
Similarly, the effects of the MYB/MAF co-silencing in
erythropoiesis were studied. Flow cytometric detection of
erythroid differentiation markers demonstrated that, whereas
MYB silencing caused a CD71+CD36-/CD71+CD36+
erythroid transition arrest, the co-silencing of MAF was able
to partially overcome this differentiation block at 4 days of
erythroid unilineage culture (Figure 6h, MYBsiRNA+MAF-
siRNA compared with MYBsiRNA), by restoring the CD71+
CD36+ and CD36+GPA- fractions (Figures 6h and i, MYB-
siRNA+MAFsiRNA compared with MYBsiRNA).
Collectively, these data demonstrate that MAF silencing in
HPCs is able to reverse at least in part the effects of MYB
silencing on erythroid versus megakaryocyte lineage choice.
Discussion
In order to shed some light on the MYB-driven miRNA-
mediated regulation of gene expression during HPCs lineage
commitment, in this study we profiled the mRNA and miRNA
expression changes induced by MYB silencing in human
CD34+ cells. The integrative analysis of miEP and GEP data
allowed us to identify 242 miRNA-mRNA pairs differentially
expressed in MYB-silenced compared with the control CD34+
cells and with the anti-correlated expression trend. Among the
miRNAswith the highest number of putative targetmRNAs, we
further investigated miR-486-3p as strongly downregulated
upon MYB silencing together with the host gene ankyrin-1
(ANK1).18,19 After showing that MYB controls miR-486-3p
expression by driving ANK1 transcription, we investigated
the role of miR-486-3p on lineage commitment through
overexpression and knockdown experiments in CD34+ cells.
We demonstrate that miR-486-3p supports erythroid and
granulocyte differentiation, while negatively interferes with
Figure 6 Rescue of MAF expression in miR-486-3p-overexpressing cells and co-silencing of MYB and MAF in CD34+ cells. (a and b) Expression kinetics of miR-486-3p
(ai, bi) andMAFmRNA (transcript variant 2) (aii, bii) during the megakaryocyte (a) and the erythroid (b) differentiation of CD34+ cells; qRT-PCR-detected modulations are reported as
RQ compared with CD34+ cells (day 0). Values in the graphs are reported as mean±S.E.M. (n= 3). (c) Flow cytometric analysis (mean± S.E.M.; n= 3) of CD41 and CD42b
expression at day 4 of megakaryocyte unilineage culture post purification of miR-486-3p/NegCTR mimic-transfected, LMAFvar2IDN/LXIDN-transduced cells. (d) Megakaryocyte
clonogenic assay results (mean±S.E.M.; n= 3) for miR-486-3p/NegCTR mimic-transfected, LMAFvar2IDN/LXIDN-transduced CD34+ cells. Cells were plated after the NGFR-
based selection of transduced cells and scored after 12 days. CFU-MKs were scored according to the manufacturer’s protocol based on their size, as reported in Figure 2 legend.
Values are reported as number of megakaryocyte colonies for 10 000 plated cells. *P≤ 0.05, **P≤ 0.01 and ***P≤ 0.001. (e) Flow cytometric detection (mean± S.E.M.; n= 3)
of CD36+GPA- and CD36+GPA+ erythroid populations at day 4 of erythroid unilineage culture post purification of miR-486-3p/NegCTR mimic-transfected, LMAFvar2IDN/LXIDN-
transduced cells. In NGFR+ cells the efficient upregulation of miR-486-3p expression was checked by qRT-PCR (RQ± SE, 58.3± 13.2 in miR-486-3p mimic/LXIDN and
67.9± 17.1 in miR-486-3p mimic/LMAFvar2IDN, NegCTR mimic/LXIDN sample set as calibrator), while MAF protein levels were detected by western blot (data not shown).
(f) Flow cytometric analysis (mean±S.E.M.; n= 4) of the CD41 expression at day 4, 8 and 12 of megakaryocyte culture post nucleofection. (g) Megakaryocyte clonogenic assay
results (mean± S.E.M.; n= 4). Cells were plated 24 hours after the last nucleofection and scored after 12 days. CFU-MKs were scored according to the manufacturer’s protocol
based on their size, as detailed in Figure 2 legend. Values are reported as number of megakaryocyte colonies for 4000 plated cells. (h and i) Flow cytometry data (mean± S.E.M.;
n= 4) for the expression of of CD71, CD36 and GPA (early, intermediate and late erythroid markers, respectively) during erythroid unilineage culture. Data reported in the graphs
display the percentages of CD71+CD36- (early) and CD71+CD36+ (intermediate) erythroid cells (h), besides the fractions of CD36+GPA- (intermediate) and CD36+GPA+ (more
mature) cells (i) at day 4 of erythroid unilineage culture post nucleofection. qRT-PCR data demonstrated that, as expected, MAF was upregulated upon MYB silencing (RQ±SE,
6.758± 0.559, Po0.01 in MYBsiRNA compared with NegCTRsiRNA, n= 4); on the contrary it was efficiently downregulated after MAF silencing in both MAFsiRNA compared
with NegCTRsiRNA (RQ±SE, 0.329± 0.035, Po0.01, n= 4) and MYBsiRNA+MAFsiRNA compared with MYBsiRNA (RQ±SE, 2.055± 0.213, Po0.05, n= 4) at 24 hours
post nucleofection. *P≤ 0.05, **P≤ 0.01 and ***P≤ 0.001. Abbreviations: CFU, colony forming unit; GPA, glycophorin A; MK, megakaryocyte; NegCTRsiRNA, negative control
siRNA; n= number of experiments
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megakaryocyte and macrophage differentiation. Indeed,
miR-486-3p overexpression restrained the megakaryocyte
differentiation and enhanced the erythroid differentiation.
Conversely, miR-486-3p knockdown impaired the erythroid
differentiation while favouring megakaryocyte differentiation.
Noteworthy, the rescue of miR-486-3p expression was able to
partially constrain the skewing of erythroid versus megakar-
yocyte fate decision detected upon MYB silencing in HPCs,
further confirming the functional relevance of miR-486-3p in
MYB-dependent control of hematopoiesis.
Next, in order to unravel the molecular mechanisms by
which miR-486-3p affects the lineage commitment and
differentiation of HPCs, we profiled the gene expression
changes upon miR-486-3p overexpression. In this way, we
identified MAF as a computationally predicted miR-486-3p
target downregulated after miR-486-3p-overexpression and
upregulated upon MYB silencing. Indeed, 30UTR reporter
assays provided the experimental evidence that MAF is a
target of miR-486-3p.
Interestingly, miR-486-3p and MAF display an anti-
correlated expression trend during both erythroid and mega-
karyocyte differentiation, further stressing the role of the
miR-486-3p/MAF axis in erythroid versus megakaryocyte
lineage choice. In order to definitively clarify the functional
role of the MYB/miR-486-3p/MAF axis, we demonstrated that
the rescue of MAF expression can restrain the effects of
miR-486-3p overexpression in erythroid and megakaryocyte
commitment. In addition, in MYB-silenced HPCs the
co-silencing of MAF partially reversed the skewing of erythroid
versus megakaryocyte lineage choice, by restraining the
expansion of megakaryocyte lineage and partially rescuing
the impairment of erythropoiesis.
As a whole, our data identify theMYB/miR-486-3p/MAFaxis
as a new molecular mechanism through which MYB favors
erythropoiesis while restraining megakaryopoiesis.
The miR-486-3p overexpression and knockdown data also
demonstrated that miR-486-3p promotes granulocyte differ-
entiation while repressing mono-macrophage differentiation.
These data, together with the anti-correlated expression levels
detected for miR-486-3p and MAF in the earlier phases of
granulocyte and mono-macrophage differentiation, strongly
suggest a role for MYB/miR-486-3p/MAF axis even in
granulocyte versus mono-macrophage lineage commitment.
As shown by Hegde et al.,11 the overexpression of MAF in
myeloid cells favors the mono-macrophage differentiation by a
MAF/MYB physical interaction negatively interfering with MYB
activity. Therefore, the MYB-driven induction of miR-486-3p
and the subsequent downregulation of MAF during the
granulocyte lineage commitment could be pivotal to elicit the
MYB-dependent transcriptional control of granulocyte lineage
priming.
Noteworthy, in agreement with Hegde et al.,11 we detected a
remarkable induction of MAF expression during mono-
macrophage differentiation (Supplementary Figure S3), also
suggesting that other mechanisms besides theMYB/miR-486-
3p/MAF axis should be inferred to explain the strong induction
of MAF expression during this process.
Respect to the aforementioned inhibitory MYB/MAF
interaction11,22,23 our data add new insights on the reciprocal
regulation of these transcription factors during hematopoietic
lineage commitment and differentiation, by demonstrating that
MYB down-regulates MAF expression levels by inducing
miR-486-3p expression.
To elucidate the molecular mechanisms of erythroid versus
megakaryocyte HPCs fate decision involving MYB, an
increasing number of studies identified miRNAs that affect
hematopoiesis by targeting MYB.24–28 However, no data
dealing with the MYB-driven transcriptional control of miRNAs
expression and the relevance of this molecular mechanism in
HPCs lineage choice were available till now.
In this study, for the first time we shed some light on the
transcriptional control of miRNA expression as a further
mechanism by which MYB regulates hematopoiesis. Of note,
GEP/miEP integrative analysis data allowed us to demon-
strate that MYB affects HPCs fate decision through the
transcriptional control of miR-486-3p expression.
In line with our data, both miR-486-3p and miR-486-5p,
generated from the processing of a commonmiR-486 precursor,
were recently reported to be upregulated during normal
erythropoiesis20,29 and in myeloid leukemogenesis.17,20,29
The demonstration that miR-486-5p, besides miR-486-3p,
affects the erythroid differentiation further emphasizes the
importance of miR-486-3p/miR-486-5p induction in MYB-
dependent control of erythropoiesis.
As a whole, here we uncover and characterize the
MYB/miR-486-3p/MAF axis (Figure 7) as a new mechanism
Figure 7 Schematic illustration of the mechanism through which the MYB/
miR-486-3p/MAF axis regulates erythroid versus megakaryocyte lineage fate
decision. MYB-mediated transactivation of ANK1 expression determines the
upregulation of miR-486-3p, which in turn targets MAF mRNA for degradation.
Therefore, through the downregulation of MAF, MYB restrains the megakaryocyte
commitment and favors the erythroid one in megakaryocyte erythroid progenitors
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underlying MYB-driven control of erythroid versus megakar-
yocyte lineage choice.
Materials and Methods
Ethics statement. Human CD34+ cells were purified upon donor’s informed
written consent from umbilical CB samples, collected after normal deliveries,
according to the institutional guidelines for discarded material (Clearance of Ethical
Commitee for Human experimentation of Modena: Secretary office Saverio
Santachiara, santachiara.saverio@policlinico.mo.it, approval date: 18.01.2005;
approval file number # 793/CE).
Human CD34+ hematopoietic progenitor cells purification. Umbi-
lical CB samples were collected after normal deliveries, according to the institutional
guidelines for discarded material. CB CD34+ cells were purified as previously
described.3 After immunomagnetic separation, CD34+ cells were seeded in 24-well
plates at 5 × 105/ml in Iscove’s modified Dulbecco’s medium (IMDM) (GIBCO, Grand
Island, NY, USA) containing 20% human serum (Bio-Whittaker, Walkersville, MD,
USA), stem cell factor (SCF) (50 ng/ml), Flt3-ligand (FLT3L) (50 ng/ml),
thrombopoietin (THPO) (20 ng/ml), interleukin-6 (IL6) (10 ng/ml) and interleukin-3
(IL3) (10 ng/ml) (all from Miltenyi Biotec, Auburn, CA, USA) and electroporated
24 hours later.
Nucleofection of CD34+ cells. Human CD34+ cells were transfected by
using the 4D-Nucleofector System (Lonza Group Ltd, Basel, Switzerland) as
previously reported.17 Briefly, starting from the day after CD34+ cell purification,
each sample was electroporated three times, once every 24 hours, with a mix of
three small interfering RNAs (siRNAs) targeting human MYB and/or MAF mRNAs
(Supplementary Table S1) (Life Technologies, Carlsbad, CA, USA). For each
electroporation, 4 × 105 CD34+ cells were resuspended in 100 μl of P3 Primary Cell
Solution (Lonza Group Ltd), containing 3 μg of siRNA mix, and pulsed with the
program DS112. To exclude non-specific effects caused by interfering RNA (RNAi)
nucleofection, one sample transfected with a non-targeting siRNA (NegCTRsiRNA;
Life Technologies) for each experiment was included.
Similarly, miRNA mimics and inhibitors transfection was performed as previously
reported.17 Briefly, CD34+ cells were nucleofected twice, once every 24 h, with 3 μg
of mirVana miR-486-3p mimic or mirVana miRNA mimic negative control (NegCTR
mimic, both from Life Technologies), by using the above mentioned electroporation
protocol DS112.
Similarly, CD34+ cells were nucleofected four times, once every 24 hours, with
3 μg of miR-486-3p miRCURY LNA Power Inhibitor or miRCURY LNA Power Inhibitor
Negative Control A, by using the electroporation protocol DS112.
At last, for the experiments of miR-486-3p rescue in MYB-silenced cells, CD34+
cells were nucleofected three times, once every 24 h, with 3 μg of mirVana miR-486-
3p/NegCTR mimic and 3 μg of MYB-targeting/NegCTRsiRNA.
RNA extraction. Total cellular RNA, including small RNAs, was isolated from
3 × 105 cells for each sample using the miRNeasy MicroRNA isolation kit (QIAGEN)
following the manufacturer’s recommendations. RNA samples concentration and
purity (assessed as 260/280 nm and 260/230 nm ratios) were evaluated by
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies; Wilmington, DE,
USA), while RNA integrity was assessed by using the Agilent 2100 Bioanalyzer
(Agilent Technologies; Waldbrunn, Germany).
Gene expression profiling (GEP). GEP was performed on RNA samples
isolated from MYB-silenced (MYBsiRNA sample) and non-targeting negative control
siRNA-transfected (NegCTRsiRNA sample) CD34+ cells at 24 h after 1, 2 and 3
nucleofections from five independent experiments. miEP was performed on the
same RNA samples isolated from CD34+ cells at 24 hours after three
nucleofections and used for GEP (n= 5).
GEP cDNA synthesis and biotin-labeled target synthesis were performed using the
GeneAtlas 30IVT Express Kit according to the protocol supplied by Affymetrix. The
HG-U219 Array Strips (Affymetrix) hybridization, staining and scanning were
performed by using the GeneAtlas Platform.
Differentially expressed genes (DEGs) were selected on robust multiarray average
(RMA)-normalized data through a supervised analysis using the ANOVA module
supplied by the Partek GS. 6.6 Software Package (http://www.partek.com). In
particular, we selected all the probesets with a fold change contrast ≥ 2 for DEGs in
the pairwise comparison between MYBsiRNA and NegCTRsiRNA samples and a
false discovery rate (FDR) (q-value)o0.05.
In a similar way, GEP was performed on RNA samples isolated from miR486-3p
mimic and NegCTR mimic CD34+ cells at 24 hours after the last nucleofection from
three independent experiments. GEP data were analyzed by using the Partek GS 6.6
Software Package as reported above, by selecting the probesets with a fold change
contrast ≥ 1.5 (Po.05) for DEGs in the pairwise comparison between miR486-3p
mimic and NegCTR mimic samples.
All the GEP data have been deposited in the NCBI's Gene Expression (GEO)
public repository30 (http://www.ncbi.nlm.nih.gov/geo; series GSE60301, subseries
GSE60299 for GEP in MYB-silenced CD34+ cells and GSE60298 for miR-486-3p
overexpressing CD34+ cells).
miRNA expression profiling (miEP). miEP was performed by using the
miRCURY LNA Universal RT microRNA PCR system, ready-to-use human
miRNome panels I and II (Exiqon) according to the manufacturer’s instructions.
For each sample, 40 ng of total RNA were reverse transcribed in 40 μl reactions.
Next, cDNAwas diluted 200-fold and assayed in 10 μl-PCR reactions according to the
protocol for miRCURY LNA Universal RT microRNA PCR protocol; each miRNA was
assayed once by qPCR on the miRNA ready-to-use PCR, Human panel I and panel II.
RT-qPCR was performed in a LightCycler 480 Real-Time PCR System (Roche,
Indianapolis, IN, USA) in the 384-well format. The Roche LightCycler software was
used in order to analyze amplification curves in order to determine threshold cycle
(Ct, by the second derivative method) and to analyze melting curve for each well.
RT-qPCR data were analyzed using the Exiqon GenEx software for the inter-plate
calibration, the definition of a Ct= 40 as detection cutoff, the labeling of not-amplified
wells as missing data and the setting of a cutoff for miRNAs with a low call-rate
(i.e. the deletion of the assays with a detection rate o30% of samples, therefore
keeping the assays detected in at least 3 out of 10 analyzed samples for further
analyses).
For RT-qPCR data normalization, the comparative cycle threshold (CT) method
was used by setting SNORD49A as reference gene, as the best normalizer identified
among the candidates by the NormFinder algorithm.31 The RQ value was expressed
as 2−ΔΔCT.
Statistical analysis on ΔCT values between MYBsiRNA and NegCTRsiRNA
sample (set as calibrator) was performed by a two-tail paired t-Student test by using
the GenEx software. Differentially expressed miRNAs (DEMs) were selected as the
miRNAs with a relative quantity (RQ) ≥ 1.5 or ≤ 0.67 (Po.05) in the pairwise
comparison between MYBsiRNA and NegCTRsiRNA samples.
The miEP data for MYB silencing experiments in CD34+ cells have been deposited
in the GEO public database30 together with the GEP data from the same samples
(http://www.ncbi.nlm.nih.gov/geo; series GSE60301, subseries 60300 for miEP data).
GEP and miEP integrative analysis. Ingenuity Pathway Analysis software
(IPA, version 8.6; Ingenuity Systems; Redwood City, CA, USA http://www.ingenuity.
com) was used to generate miRNA–mRNA interactions between the DEMs and
their putative target differentially expressed genes (DEGs) with anti-correlated
expression upon MYB silencing in CD34+ cells at 24 hours after the last
nucleofection. IPA combines computationally predicted targets with gene expression
data. Through the microRNA Target Filter, IPA software enables the identification of
the DEMs putative targets within the DEG list according to at least one out of four
different databases (TargetScan, miRecords, Tarbase or Ingenuity expert findings).
miR-486-3p and MAF kinetics during erythroid, megakaryocyte,
granulocyte and mono-macrophage differentiation. After immuno-
magnetic separation, CD34+ cells were seeded in 24-well plates at a density of
5 × 105/ml in serum-free medium SYN-H (ABCell-Bio, Paris, France) supplemented
with SCF (10 ng/ml), IL-3 (2 ng/ml) and IL-6 (1 ng/ml). After a first phase of
expansion, at 6 days of culture the cells were seeded (5 × 105/ml) in IMDM added
with 20% BIT serum substitute (bovine serum albumin, insulin, and transferrin;
StemCell Technologies, Vancouver, BC, Canada), SCF (10 ng/ml), IL-3 (2 ng/ml),
IL-6 (1 ng/ml) and EPO (4 U/ml) to induce erythroid differentiation. The medium was
replaced every 3 days. miR-486-3p, MAF and ANK1 expression levels were
detected by qRT-PCR at different time points (i.e. days 0, 2, 4 and 6) after the
seeding of cells in erythroid differentiation-inducing culture conditions.
In a similar way, after immunomagnetic sorting, CD34+ cells were seeded in 24-
well plates at a density of 5 × 105/ml in serum-free medium SYN-H (ABCell-Bio, Paris,
France) supplemented with SCF (50 ng/ml), FLT3L (50 ng/ml), THPO (20 ng/ml), IL-3
(10 ng/ml) and IL-6 (10 ng/ml). After a first phase of expansion, at 4 days of culture the
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cells were seeded (5 × 105/ml) in IMDM added with 20% BIT serum substitute (bovine
serum albumin, insulin and transferrin; StemCell Technologies) in order to set up
megakaryocyte (THPO 50 ng/ml, SCF 10 ng/ml, adapted from Tenedini et al.32),
granulocyte (GCSF 25 ng/ml, SCF 10 ng/ml, adapted from Kandilci et al.33) and
monocyte (MCSF 100 ng/ml, SCF 20 ng/ml, IL6 20 ng/ml and Flt3L 50 ng/ml33)
unilineage cultures (all cytokines from Miltenyi Biotec). The medium was replaced
every 3 days. CD34+ cells differentiation was monitored by by morphological analysis
of MGG-stained cytospins and by flow-cytometric analysis of differentiation marker
expression. miR-486-3p and MAF expression levels were detected by qRT-PCR at
different time points (i.e. days 0, 2, 4, 6 and 8) after the seeding of cells in
megakaryocyte, granulocyte or mono-macrophage unilineage cultures.
Quantitative reverse transcription polymerase chain reaction.
Total RNA (100 ng) was reverse-transcribed to cDNA using a High Capacity cDNA
Archive Kit (Life Technologies). TaqMan PCR was carried out by using the TaqMan
Fast Advanced PCR master mix and TaqMan gene expression assays (all reagents
from Life Technologies), by means of a 7900HT Fast Real-Time PCR System
(Applied Biosystems). Assays were performed in triplicate. Gene expression
profiling was achieved using the comparative cycle threshold (CT) method of
relative quantitation using hypoxanthine phosphoribosyltransferase 1 (HPRT1) as
the housekeeping gene. To normalize data, ΔΔCT was calculated for each sample
using the mean of its ΔCT values subtracted from the mean ΔCT value measured
in the MOCK sample, set as a calibrator; relative quantitation (RQ) value was
expressed as 2−ΔΔCT.
Individual miRNA detection by RT-qPCR was performed using the TaqMan
MicroRNA assays (Life technologies). Individual reverse transcription reactions (5 ng
of total RNA each target) were performed using the Taqman microRNA Reverse
Transcription Kit and the miRNA-specific looped-primers. TaqMan PCR was
performed in triplicate by using the 7900HT Fast Real-Time PCR System (Applied
Biosystems). miRNA expression RQ data were calculated as reported above, by
using SNORD49A as the housekeeping control.
Chromatin ImmunoPrecipitation. ChIP assay was performed as reported
by Lang et al.34 with some modifications. After crosslinking in 1% formaldehyde,
highly proliferating CB-derived CD34+ cells (10 × 106 cells/sample) were
resuspended in 2 ml lysis buffer (5 mM PIPES, 85 mM KCl, 0.5% NP-40, protease
inhibitors (Roche), 1 mM PMSF) and disrupted with a Dounce homogenizer, then
incubated on ice for 10 min. Nuclei were pelleted and resuspended in 1 ml
sonication buffer (0.1% SDS, 10 mM EDTA pH 8, 50 mM Tris pH 8, protease
inhibitors (Roche), 1 mM PMSF) and incubated on ice for 10 min. Chromatin with an
average size of 500–1000 bp was produced by sonication. Debris were cleared by
centrifugation. Chromatin (100 μl for each sample) was diluted twofold into RIPA
buffer (10 mM TrisHCl pH8, 1 mM EDTA pH8, 0.5 mM EGTA, 1%Triton X-100, 0,1%
Na-deoxycholate, 0,1% SDS, 140 mM NaCl, 1 mM PMSF and protease inhibitors
(Roche) and pre-cleared with Protein G Agarose slurry (KPL, Gaithersburg, MD,
USA), then immunoprecipitated with (MYB sample) or without (no-antibody sample)
mouse monoclonal anti-MYB antibody (Anti-MYB, clone 1-1, catalog #27282,
Upstate, Lake Placid, NY) overnight at 4 °C with rotation. A negative control (named
IgG CTR) sample incubated with an isotype-matched non-specific antibody
(Upstate, Lake Placid, NY, USA) was included. Protein G Agarose slurry (KPL) was
pre-cleared in RIPA buffer with 1 μg/μl salmon sperm DNA and 1 μg/μl BSA
overnight at 4 °C with rotation and then washed twice in ChIP buffer. Immune
complexes were collected by incubation with pre-cleared protein G agarose for 2 h
with rotation at 4 °C. The supernatant fraction of the no-antibody sample was
collected as total input chromatin. The protein G agarose/antibody/chromatin
complex was washed five-fold with RIPA buffer, then once with LiCl buffer buffer
(250 mM LiCl, 0.5%NP40, 0.5% Na deoxycholate, 1 mM EDTA, 10 mM TrisHCl pH8)
and TE buffer (1 mM EDTA, 10 mM TrisHCl pH8) respectively. Beads were
resuspended in 100 μl of TE buffer. Samples were incubated with RNase A
overnight at 65 °C, then with 0.5% SDS and 0.5 mg/ml proteinase K at 50 °C for 3 h.
Immunoprecipitated DNA samples were isolated by phenol-chloroform extraction,
precipitated in ice-cold ethanol at − 20 °C and resuspended in 30 μl of distilled
water. Primers for PCR were as follows: ANK1 (−1292/− 1287) forward:
gaagctgatctcggtggcat; ANK1 (−1292/− 1287) reverse: cgtgatgcttggcctcctg; ANK1
(−1008/999) forward: ggaaaccatggagggagaca; ANK1 (−1008/999) reverse:
gtccaacaacgggatgagatg; CTSG forward: TTG ATG GGT TGA GGG TTC TGG;
CTSG reverse: CAG TCA GTT GCT GCT GTG CTT C. CTSG promoter-specific
PCR was included as a positive control for MYB antibody-mediated ChIP, since
CTSG has already been demonstrated to be a MYB target gene.35 ChIP reactions
were done at least twice for each preparation using three different preparations of
CD34+ cells. Data shown are for 32 cycles.
Luciferase reporter assay. The human ANK1 promoter reporter construct
was made by cloning the proximal − 1498/+47 fragment of ANK1 promoter into the
promoterless vector pXP1 containing Firefly luciferase reporter gene.
The human ANK1 promoter − 1498/+47 clone was made by amplifying the PCR
product by using forward CGCGGATCCGCGTTAAGGACTGTGCTGTGGTAGA
(BamHI) and reverse GGAAGATCTTCCGGGCTTGAGGAGGAGCA (BglII) primers,
cutting with the restriction enzymes BamHI and BglII and inserting it into pXP1 vector
using these sites.
The cloned fragment for ANK1 promoter region was amplified from genomic DNA
of human CB CD34+ cells and originally inserted in pCR2.1 vector (Invitrogen). The
sequences of all promoter constructs were verified by sequencing.
Approximately 1–1.5 × 105 HEK293T cells were transiently transfected with
Lipofectamine 2000 (Invitrogen) using 100 to 400 ng of pCMV6XL5-MYB vector
(Origene, Rockville, MD), 200 ng of ANK1-Firefly luciferase, 2 ng of pGL4.75 hRLuc/
CMV (Promega, Madison, WI, USA), and carrier plasmid to level the total amount of
transfected DNA for all the samples. Firefly and Renilla luciferase activity was
measured 48 h after the transfection using the Dual-Luciferase Reporter Assay
System (Promega) and luminescence was recorded on a GloMax-Multi+ Detection
System with Intinct Software (Promega), according to the manufacturer’s protocol.
Five independent experiments were performed in duplicate. Firefly luciferase activity
was normalized to that of Renilla luciferase.
CD34+ cells culture conditions. After immunomagnetic separation, CD34+
cells were seeded in 24-well plates at 5 × 105/ml in IMDM (Euroclone) containing
20% human serum (Bio-Whittaker), stem cell factor (SCF; 50 ng/ml), Fms-like
tyrosine kinase 3 ligand (Flt3L; 50 ng/ml), thrombopoietin (THPO; 20 ng/ml),
interleukin-6 (IL-6; 10 ng/ml) and interleukin-3 (IL-3; 10 ng/ml; all from Miltenyi).
After each transfection, cells were transferred into pre-warmed fresh medium in 24-
well plates and maintained in the same culture conditions as described above.
For liquid culture differentiation assays, 24 h after the last nucleofection (hereafter
reported as post nucleofection) CD34+ cells were plated (5 × 105/ml) in IMDM added
with 20% BIT serum substitute (bovine serum albumin, insulin, and transferrin;
StemCell Technologies), in order to set up erythroid (erythropoietin (EPO) 0.4 U/ml,
SCF 10 ng/ml, adapted from Bianchi et al.,3 megakaryocyte (THPO 50 ng/ml, SCF
10 ng/ml, adapted from Tenedini et al.32), granulocyte (GCSF 25 ng/ml, SCF 10 ng/ml,
adapted from Kandilci et al.33) and monocyte (MCSF 100 ng/ml, SCF 20 ng/ml, IL6
20 ng/ml and Flt3L 50 ng/ml;33 all cytokines from Miltenyi Biotec) unilineage cultures.
The medium was replaced every 3 days.
Morphological and immunophenotypic analysis. Differentiation of
CD34+ cells was assessed by morphological analysis of MGG-stained cytospins at
8, 11 and 13 days post nucleofection and by flow-cytometric analysis of
differentiation markers expression (CD34, CD71, CD36, Glycophorin A (GPA),
CD15, myeloperoxydase (MPO), CD14, CD163, CD41, CD42b) at 4, 8, 10 and
12 days post nucleofection.
The images were captured by using an Ax10scopeA1 microscope equipped with
an AxioCam ERc 5S Digital Camera and Axion software 4.8 (all Carl Zeiss
MicroImaging Inc.; Thornwood, NY, USA). The images were then processed with
Adobe Photoshop 7.0 software.
The following monoclonal antibodies (MoAbs) were used for flow-cytometric
analysis: fluorescein isothiocyanate (FITC)-conjugated mouse anti-CD41 MoAb,
PE-conjugated mouse anti-human CD42b MoAb, PE-conjugated mouse anti-human
GPA MoAb (all from Dako; Milano, Italia; http://www.dako.com), VioBlue-conjugated
mouse anti-CD34 MoAb, FITC-conjugated mouse anti-human CD15 MoAb, FITC-
conjugated mouse anti-human CD36 MoAb, allophycocyanin (APC)-conjugated
mouse anti-human CD71 MoAb, PE-conjugated mouse anti-human CD14 MoAb,
APC-conjugated mouse anti-human CD163 MoAb (all from Miltenyi Biotec) and
FITC-conjugated mouse anti-human MPO MoAb (from BD Biosciences; San Jose,
CA USA). After staining, cells were analyzed by using a BD FACSCanto II
(BD Biosciences). At least 10 000 events were counted for each sample to ensure
statistical relevance.
Collagen-based megakaryocyte clonogenic assay. CFU-MK were
assayed in collagen-based medium, by using a commercial Mk assay detection kit
(MegaCult-C, StemCell Technologies) as previously described.3 CFU-MKs were
scored according to the manufacturer’s protocol as small (3–21 cells, deriving from
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more mature megakaryocyte progenitors), medium (21–49 cells) and large (450
cells, arising from more primitive MK progenitors) colonies based on their size,
which reflects the maturation stage of the progenitor giving rise to each colony.
30 Untranslated region (30UTR) luciferase reporter assays. Full-
length 30UTR from MAF variant 1 (RefSeq NM_005360.3) and MAF variant
2 (NM_001031804.1; given its size, the latter 30UTR was cloned in two fragments,
1–2569 bps and 2530–4932 bps, respectively) transcripts and empty pEZX-MT01
luciferase reporter constructs were purchased from Labomics (Genecopoeia; MD,
USA). Every plasmid contains the firefly luciferase gene upstream of a given
30 untranslated region (30UTR), and the Renilla luciferase gene acting as a
normalizer gene.
K562 cells were electroporated by means of the Amaxa 4D-Nucleofector System
(Lonza Group Ltd), according to the manufacturer's instructions. Briefly, K562 cells
were co-nucleofected with either a miR-486-3p mimic or NegCTR mimic at a
concentration of 3.6 μM and with either 30UTR-less luciferase or a full-length 30UTR
construct at a concentration of 0.4 pmol/sample. For each electroporation, 106 cells
were resuspended in 100 μl of SF Cell line Solution (Lonza Group Ltd) and pulsed
with the program FF120. Firefly and Renilla luciferase activities were measured at 24,
48 and 72 h after nucleofection using the Dual-Luciferase Reporter Assay System
(Promega), and luminescence was recorded on a GloMax-Multi+ Detection System
with Intinct Software (Promega), according to the manufacturer’s protocol.
Firefly luciferase activity was first normalized to that of Renilla luciferase as an
internal control for nucleofection efficiency. Next, for each 30UTR luciferase reporter
construct the luminescence signal was normalized to the effect of the NegCTR
mimic-transfected sample.
Western blot. MAF protein levels in both miR-486-3p/NegCTR mimic-
transfected and in LMAFvar2IDN/LXIDN-transduced CD34+ cells were detected
by western blot analysis. Briefly: cells were harvested, washed twice with ice-cold
PBS and lysed (5 × 105 cells/20 μl of lysis buffer) in 50 mM Tris (tris(hydroxymethyl)
aminomethane)-Cl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, 10 mM KCl, 1 mM
EDTA, 20 mM NaF, 0.25% Na doexycholate, 5 mM dithiothreitol (DTT) and protease
inhibitors (Complete, catalog #1697498, Roche). Total cellular lysates (15 μg for
each sample) were loaded onto 12.5% SDS-polyacrylamide gel and blotted on
nitrocellulose membrane. To control loading and transfer, after transfer the
membranes were stained by Red Ponceau. Membranes were then preblocked in
blocking solution, 5% milk in 0.1% TBST for 1 h at room temperature (RT),
incubated with primary antibodies (1 : 2000 dilution of rabbit monoclonal anti-MAF
antibody (1 : 2000 dilution, catalog #181188, Abcam, Cambridge, UK;
www.abcam.com), at 4 °C overnight of rabbit polyclonal anti–actin antibody
(1 : 5000 dilution, Thermo Fisher Scientific Inc., Waltham, MA, USA, catalog #PA1-
16889) for 1 h at RT. After three washes with TBST, blots were incubated with HRP-
conjugated goat anti-rabbit secondary antibody (1 : 1000 dilution, Thermo Fisher
Scientific Inc.) for 1 h at RT and revealed by BM Chemiluminescence Blotting
Substrate (POD) (Roche).
CD34+ cells transduction and purification. In order to achieve the
overexpression of both miR-486-3p and MAF in human progenitor cells (HPCs),
CD34+ cells were nucleofected with miR-486-3p/NegCTR mimic as already
described in ‘nucleofection of CD34+ cells’. Next, 12 h after the second
nucleofection, CD34+ cells were transduced in 24-wells plates at a density of
5 × 105/ml in serum-free medium SYN-H (ABCell-Bio, Paris, France) supplemented
with SCF (50 ng/ml), FLT3L (50 ng/ml), THPO (20 ng/ml), IL-3 (10 ng/ml) and IL-6
(10 ng/ml; all cytokines from Miltenyi Biotec). CD34+ cells were transduced by
means of three cycles of infection (12 h each) with viral supernatant in the presence
of polybrene (8 μg/ml) in retronectin-coated plates (10 μg/cm2). After transduction,
cells were maintained in the same culture conditions reported above for 36 h.
Transduction efficiency was monitored by flow-cytometric detection of the NGFR-
positive (NGFR+) fraction after labeling with a PE-conjugated anti-NGFR antibody
(Miltenyi Biotec). Transduced CD34+ cells were subsequently purified by an
immunomagnetic procedure (EasySep ‘Do-It-Yourself’ Selection Kit; StemCell
Technologies) by means of a anti-human p75-NGFR mouse monoclonal antibody
(BD Biosciences) and seeded in the liquid culture conditions as reported above.
NGFR+ cells were analyzed for both MAF and miR-486-3p expression by qRT-
PCR. CFU-MK were assayed by plating 10 000 NGFR+ cells for sample in collagen-
based medium, as already described above. For liquid culture differentiation assays,
NGFR+ cells were plated (5 × 105/ml) in: (a) serum-free medium SYN-H (ABCell-Bio,
Paris, France) supplemented with SCF (5 ng/ml), THPO (50 ng/ml), IL11 (40 ng/ml),
IL3 (2 ng/ml) and IL6 (1 ng/ml) in order to support the differentiation towards the
megakaryocyte lineage; (b) IMDM added with 20% BIT serum substitute (bovine
serum albumin, insulin, and transferrin; StemCell Technologies) supplemented with
erythropoietin (EPO; 0.4 U/ml; Neorecormon, Roche) and SCF (10 ng/ml; Miltenyi) in
order to support the erythroid differentiation. The medium was replaced every 2 days.
Differentiation was assessed by morphological analysis of MGG-stained cytospins
and by flow-cytometric analysis of CD41, CD42b, CD71, CD36 and GPA
differentiation markers.
Statistical analysis. The statistics used for data analysis in silencing/over-
expression experiments and luciferase reporter assays were based on two-tailed
Student’s t-tests for averages comparison in paired samples. Data were analyzed by
using Microsoft Excel (Microsoft Office, 2008 release, Microsoft, Redmont, WA, USA)
and are reported as mean±S.E.M.. Po0.05 was considered significant.
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